3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
25
Advanced Breast Cancer
2
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
ESR1 Gene Mutation
1
ER+ Breast Cancer
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Breast Diseases
1
Breast Cancer Patients
1
Brain Neoplasms
1
Brain Diseases
1
Advanced ER+, HER2-Negative Breast Cancer
1
Interventions
Paclitaxel
50
Capecitabine
50
Trastuzumab
38
Fulvestrant
31
pembrolizumab
27
Cyclophosphamide
27
Carboplatin
27
Gemcitabine
23
Letrozole
21
palbociclib
19
Docetaxel
19
Lapatinib
18
Bevacizumab
18
exemestane
17
eribulin
15
Everolimus
14
abemaciclib
13
Vinorelbine
13
Nivolumab
13
Magnetic Resonance Spectroscopy
12
Cisplatin
12
Anastrozole
12
trastuzumab deruxtecan
11
Zoledronic Acid
11
Doxorubicin
11
Albumin-Bound Paclitaxel
11
olaparib
10
Tamoxifen
10
Specimen Handling
10
Radiotherapy
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
elacestrant
×
Breast
×
Clear all
NCT06201234
2025-12-01
ELEMENT
GBG Forschungs GmbH
Phase 2
Recruiting
176 enrolled